|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Klein T and Bischoff R: Active
metalloproteases of the A disintegrin and metalloprotease (ADAM)
family: biological function and structure. J Proteome Res.
10:17–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Seals DF and Courtneidge SA: The ADAMs
family of metalloproteases: multidomain proteins with multiple
functions. Genes Dev. 17:7–30. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee SB, Schramme A, Doberstein K, et al:
ADAM10 is upregulated in melanoma metastasis compared with primary
melanoma. J Invest Dermatol. 130:763–773. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gaida MM, Haag N, Günther F, et al:
Expression of A disintegrin and metalloprotease 10 in pancreatic
carcinoma. Int J Mol Med. 26:281–288. 2010.PubMed/NCBI
|
|
7
|
Wang YY, Ye ZY, Li L, Zhao ZS, Shao QS and
Tao HQ: ADAM 10 is associated with gastric cancer progression and
prognosis of patients. J Surg Oncol. 103:116–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ko SY, Lin SC, Wong YK, Liu CJ, Chang KW
and Liu TY: Increase of disintergin metalloprotease 10 (ADAM10)
expression in oral squamous cell carcinoma. Cancer Lett. 245:33–43.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang W, Liu S, Liu K, et al: A
disintegrin and metalloprotease (ADAM)10 is highly expressed in
hepatocellular carcinoma and is associated with tumour progression.
J Int Med Res. 42:611–618. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Endres K and Fahrenholz F: Upregulation of
the α-secretase ADAM10 - risk or reason for hope? FEBS J.
277:1585–1596. 2010.
|
|
11
|
Murai T, Miyazaki Y, Nishinakamura H, et
al: Engagement of CD44 promotes Rac activation and CD44 cleavage
during tumor cell migration. J Biol Chem. 279:4541–4550. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yue Y, Shao Y, Luo Q, Shi L and Wang Z:
Downregulation of ADAM10 expression inhibits metastasis and
invasiveness of human hepatocellular carcinoma HepG2 cells. Biomed
Res Int. 2013:4345612013.PubMed/NCBI
|
|
13
|
Mora LB, Buettner R, Seigne J, et al:
Constitutive activation of Stat3 in human prostate tumors and cell
lines: direct inhibition of Stat3 signaling induces apoptosis of
prostate cancer cells. Cancer Res. 62:6659–6666. 2002.PubMed/NCBI
|
|
14
|
Angell JE, Lindner DJ, Shapiro PS, Hofmann
ER and Kalvakolanu DV: Identification of GRIM-19, a novel cell
death-regulatory gene induced by the interferon-β and retinoic acid
combination, using a genetic approach. J Biol Chem.
275:33416–33426. 2000.PubMed/NCBI
|
|
15
|
Alchanati I, Nallar SC, Sun P, et al: A
proteomic analysis reveals the loss of expression of the cell death
regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene.
25:7138–7147. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang L, Gao L, Li Y, et al: Effects of
plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3M
tumor cell growth. Clin Cancer Res. 14:559–568. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li F, Ren W, Zhao Y, et al: Downregulation
of GRIM-19 is associated with hyperactivation of p-STAT3 in
hepatocellular carcinoma. Med Oncol. 29:3046–3054. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lufei C, Ma J, Huang G, et al: GRIM-19, a
death-regulatory gene product, suppresses Stat3 activity via
functional interaction. EMBO J. 22:1325–1335. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang J, Yang J, Roy SK, et al: The cell
death regulator GRIM-19 is an inhibitor of signal transducer and
activator of transcription 3. Proc Natl Acad Sci USA.
100:9342–9347. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang Y, Yang M, Yang H and Zeng Z:
Upregulation of the GRIM-19 gene suppresses invasion and metastasis
of human gastric cancer SGC-7901 cell line. Exp Cell Res.
316:2061–2070. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang G, Chen Y, Lu H and Cao X: Coupling
mitochondrial respiratory chain to cell death: an essential role of
mitochondrial complex I in the interferon-β and retinoic
acid-induced cancer cell death. Cell Death Differ. 14:327–337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hao H, Liu J, Liu G, et al: Depletion of
GRIM-19 accelerates hepatocellular carcinoma invasion via inducing
EMT and loss of contact inhibition. J Cell Physiol. 227:1212–1219.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin Y, Peng S, Yu H, et al: RNAi-mediated
downregulation of NOB1 suppresses the growth and
colony-formation ability of human ovarian cancer cells. Med Oncol.
29:311–317. 2012.
|
|
24
|
Wen LJ, Gao LF, Jin CS, et al: Small
interfering RNA survivin and GRIM-19 co-expression salmonella
plasmid inhibited the growth of laryngeal cancer cells in vitro and
in vivo. Int J Clin Exp Pathol. 6:2071–2081. 2013.PubMed/NCBI
|
|
25
|
Wang GM, Ren ZX, Wang PS, et al:
Plasmid-based Stat3-specific siRNA and GRIM-19 inhibit the growth
of thyroid cancer cells in vitro and in vivo. Oncol
Rep. 32:573–580. 2014.PubMed/NCBI
|
|
26
|
Li X, Li Y, Hu J, et al: Plasmid-based
E6-specific siRNA and co-expression of wild-type p53 suppresses the
growth of cervical cancer in vitro and in vivo. Cancer Lett.
335:242–250. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
|
|
28
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chau BN and Wang JY: Coordinated
regulation of life and death by RB. Nat Rev Cancer. 3:130–138.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yau WL, Lam CS, Ng L, et al:
Over-expression of miR-106b promotes cell migration and metastasis
in hepatocellular carcinoma by activating epithelial-mesenchymal
transition process. PLoS One. 8:e578822013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yuan S, Lei S and Wu S: ADAM10 is
overexpressed in human hepatocellular carcinoma and contributes to
the proliferation, invasion and migration of HepG2 cells. Oncol
Rep. 30:1715–1722. 2013.PubMed/NCBI
|
|
32
|
Xue YJ, Xiao RH, Long DZ, et al:
Overexpression of FoxM1 is associated with tumor progression in
patients with clear cell renal cell carcinoma. J Transl Med.
10:2002012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Braicu EI, Gasimli K, Richter R, et al:
Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to
adjuvant radiochemotherapy in patients with primary cervical cancer
- results of a companion protocol of the randomized NOGGO-AGO phase
III clinical trial. Anticancer Res. 34:385–391. 2014.
|
|
34
|
Lai WW, Hsu SC, Chueh FS, et al: Quercetin
inhibits migration and invasion of SAS human oral cancer cells
through inhibition of NF-κB and matrix metalloproteinase-2/-9
signaling pathways. Anticancer Res. 33:1941–1950. 2013.PubMed/NCBI
|
